KIF16B

Across TCGA pan-cancer cohorts, KIF16B RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated KIF16B data layer compared with 5 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KIF16B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KIF16B expression acts as an unfavorable survival marker, although some lineages such as KIRC and SKCM show a favorable association.

BLCA, KIRC, and LGG are the cancer types where KIF16B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	III,IV	0.418	0.671	.001	101	view →
KIRC	DFS	Median	All	0.717	0.545	<.001	100	view →
LGG	DFS	Median	All	0.648	0.833	<.001	54	view →
LAML	DFS	Quartile	All	0.289	0.611	<.001	36	view →
LUSC	OS	Tertile	III,IV	0.251	0.611	.002	29	view →
SKCM	DFS	Quartile	All	0.267	0.134	<.001	19	view →
SCLC	DFS	Quartile	II,III,IV	0.156	0.806	.024	15	view →
LIHC	OS	Quartile	All	0.621	0.805	.005	15	view →
UCS	DFS	Tertile	IV	0.871	0.361	.024	12	view →
BRCA	DFS	Tertile	IV	0.845	0.360	.010	10	view →
ACC	DFS	Tertile	All	0.500	0.818	.003	7	view →
MESO	OS	Median	All	0.312	0.454	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

KIF16B–BLCA (OS)

Open the BLCA breakdown →